SARS-CoV-2感染对急性胰腺炎患者预后及死亡率的影响评估
本研究为单中心回顾性观察研究,纳入2020年3月10日至12月31日急诊诊断急性胰腺炎的189例成人患者,按RT-PCR结果分为COVID-19阳性与阴性两组。阳性患者ICU需求为7.23%,高于阴性患者的0.94%;阳性患者重症AP比例为32.53%,高于阴性患者的14.15%(p<0.03)。提示合并COVID-19的AP患者需更严密监护与资源准备。
要点
- 合并COVID-19的AP患者ICU入住率为7.23%,显著高于无COVID-19患者的0.94%。
- 合并COVID-19的AP患者重症AP比例为32.53%,无COVID-19者为14.15%(p<0.03)。
- 合并COVID-19相关肺炎的AP患者死亡风险进一步升高,需加强监护与治疗策略。
- 本研究为单中心回顾性观察研究,结论需前瞻性验证。
适用人群与场景
- 年龄>18岁、在当前疫情期间于急诊就诊并诊断为急性胰腺炎的患者。
- 按RT-PCR结果分为COVID-19阳性组与阴性组进行比较。
诊断标准与关键阈值
- 急性胰腺炎诊断依据原文未具体说明。
- COVID-19分组依据RT-PCR检测结果。
- 重症急性胰腺炎定义原文未具体说明。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- COVID-19阳性合并急性胰腺炎患者的重症比例(32.53%)与ICU需求(7.23%)更高,需警惕病情恶化。
- CT示COVID-19兼容性肺炎、CCI≥5、BISAP评分升高与死亡率相关,应加强监测。
研究设计与关键结果
- 研究类型:单中心、回顾性、观察性研究;共筛查562例急诊急性胰腺炎患者,最终纳入189例。
- 主要结果:COVID-19阳性患者ICU需求7.23%,阴性患者0.94%。
- COVID-19阳性患者重症AP比例32.53%,阴性患者14.15%(p<0.03)。
证据类型、等级与局限
- 证据类型:单中心回顾性观察性研究。
对床旁实践的改变
- 对合并COVID-19的急性胰腺炎患者应提高ICU转入警惕,因其ICU需求与重症比例更高。
- 对CT示COVID-19兼容性肺炎、CCI≥5或BISAP评分升高的AP患者应加强死亡风险评估与监护。
- 原文未提供具体治疗调整方案,不能据此改变药物或液体复苏策略。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Acute pancreatitis (AP) is the leading cause of hospitalization among gastrointestinal disorders. The aim of our study is to compare the results between AP patients with and without COVID-19, and to reveal the effects of COVID-19 on the course, intensive care needs and mortality of AP patients.
MATERIAL METHODS: This was a single-center, retrospective and observational study. Patients over 18 years of age, who were diagnosed with AP during the current pandemic. According to the RT-PCR test result, patients were divided into two groups: COVID-19 positive and COVID-19 negative. Gender, age, laboratory parameters, intensive care unit admission, length of hospital stay, severity and mortality of AP were compared between these two groups.
RESULTS: We reviewed 562 patients presenting to the emergency department who were diagnosed with acute pancreatitis between 10.03.2020 and 31.12.2020 and included 189 patients in our study. Positive patients need for intensive care (7.23%) were higher compared to negative patients (0.94%). 32.53% of positive patients and 14.15% of negative patients had severe AP (p < 0.03). We established that being COVID-19 positive, CCI scores of ≥5, presence of COVID-19 compatible pneumonia on CT and BISAP scores had an effect on mortality (p < 0,05).
CONCLUSION: The severity and mortality of AP increase in patients with both AP and COVID-19. This rate increases even more in the presence of COVID-19-associated pneumonia. We believe that new strategies should be developed for the follow-up and treatment of patients with both these conditions.
参考来源
- Karaali R, Topal F. Evaluating the effect of SARS-Cov-2 infection on prognosis and mortality in patients with acute pancreatitis. Am J Emerg Med. 2021. PMID: 34246968. doi:10.1016/j.ajem.2021.06.045
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。